MYLAN 2047 MYLAN 2047 (Tacrolimus 5 mg)
Pill with imprint MYLAN 2047 MYLAN 2047 is Gray & Red, Capsule-shape and has been identified as Tacrolimus 5 mg. It is supplied by Mylan Pharmaceuticals Inc.
Tacrolimus is used in the treatment of organ transplant, rejection prophylaxis; organ transplant, rejection reversal and belongs to the drug class calcineurin inhibitors. Risk cannot be ruled out during pregnancy. Tacrolimus 5 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for MYLAN 2047 MYLAN 2047


Tacrolimus
- Imprint
- MYLAN 2047 MYLAN 2047
- Strength
- 5 mg
- Color
- Gray & Red
- Size
- 14.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Calcineurin inhibitors
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Mylan Pharmaceuticals Inc.
- Inactive Ingredients
-
lactose anhydrous,
ferrosoferric oxide,
silicon dioxide,
croscarmellose sodium,
gelatin,
hypromelloses,
lactose monohydrate,
magnesium stearate,
sodium lauryl sulfate,
titanium dioxide,
ferric oxide yellow,
D&C Red No. 28,
D&C Yellow No. 10,
D&C Red No. 33,
FD&C Blue No. 1,
FD&C Blue No. 2,
FD&C Red No. 40,
propylene glycol,
shellac
Note: Inactive ingredients may vary.
Labelers / Repackagers
NDC Code | Labeler / Repackager |
---|---|
00378-2047 | Mylan Pharmaceuticals Inc. |
51079-0028 | UDL Laboratories Inc. |
More about tacrolimus
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (45)
- Drug images
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: calcineurin inhibitors
Patient resources
- Drug Information
- Tacrolimus Intravenous (Advanced Reading)
- Tacrolimus Oral, Intravenous (Advanced Reading)
- Tacrolimus Extended-Release Tablets
- Tacrolimus Capsules
- Other brands
- Prograf, Envarsus XR, Astagraf XL, Hecoria
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.